Title: China Advances Hepatitis B Vaccine Production Using Genetic Engineering
Author: Yang Zhaobo
Date: 1989-10-24
Edition: 2

China has successfully developed a hepatitis B vaccine using genetic engineering technology, and it has now entered the trial production stage.

According to reports, this achievement is the top priority of the national "Seventh Five-Year Plan" key projects. It will meet the urgent need for hepatitis B prevention in China. It is expected that by the end of 1990, the production capacity will reach 100,000 doses. With the production of the hepatitis B vaccine, it will be possible to administer injections to hepatitis B patients and carriers, thereby controlling the spread of this disease in China.

It is understood that the conventional method of producing hepatitis B antibodies is to extract a small amount of antibodies from a large amount of blood plasma containing the virus. However, the current use of genetic engineering methods has increased the yield by more than 100 times compared to the original method.


<hr /> 

Original: 


### 我运用基因工程技术攻关  乙肝疫苗进入试制阶段
杨兆波
1989-10-24
第2版(国内新闻)
专栏：

　　我运用基因工程技术攻关
　　乙肝疫苗进入试制阶段
    据新华社北京10月23日电　（记者杨兆波）我国基因工程乙型肝炎疫苗研制成功，目前已进入试制阶段。
    据介绍，这项成果是国家“七五”攻关的头号任务，它将满足我国预防乙肝的迫切需要。预计1990年底将形成100万人份的生产能力。随着乙肝疫苗的生产，将可对乙肝病人及带毒者实施注射，从而在我国抑制这种病的发展。
    据了解，通常生产乙肝抗体的办法是从大量带有病毒的血浆中提取少量的抗体，而目前采用基因工程的方法比原来的方法在产量上提高了100倍以上。
